ArriVent BioPharma, Inc. AVBP 深 沪
已收盘 10-31 16:00:00 美东时间
18.73
+0.260
+1.41%
华盛通- 最 高18.98
- 今 开18.64
- 成交量 24.55万股
- 最 低 18.00
- 昨 收 18.47
- 总市值 7.60亿
- 52周最高 34.92
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 15.47
- 委 比 75.55%
- 总股本 4056.89万
- 历史最高 36.37
- 量 比 0.60
- 振 幅 5.31%
- 历史最低 14.35
- 每 手 1
- 风险率 4.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma announced the appointment of Brent S. Rice as Chief Commercial Officer. With over 25 years of experience in biotech and pharma, Rice will lead commercial efforts for firmonertinib, a potential treatment for EGFR mutant NSCLC, and advance the company's ADC portfolio. Previously, Rice served as CCO at Autolus Therapeutics and held leadership roles at Amgen and Juno Therapeutics, demonstrating success in launching therapies and bu...
09-22 20:05
ArriVent BioPharma Presents Final Proof-Of-Concept Data From Randomized Global Phase 1b FURTHER Trial For First-Line Firmonertinib Monotherapy In Patients With NSCLC Harboring EGFR PACC Mutations At IASCLC 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR)
09-09 20:07
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
ArriVent BioPharma presented positive data from the Phase 1b FURTHER trial of firmonertinib in first-line NSCLC patients with EGFR PACC mutations. Key findings include a 16.0-month median progression-free survival (mPFS) and a 68.2% confirmed overall response rate (cORR). Firmonertinib also demonstrated CNS responses, including complete responses, and rapidly cleared PACC ctDNA across mutation types. Enrollment in the Phase 3 ALPACCA trial is exp...
09-09 12:00
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $33
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $33.
08-12 19:41
ArriVent BioPharma Advances Cancer Therapeutics Pipeline
ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q2 earnings. Here is a br...
08-12 12:18
ArriVent BioPharma Q2 EPS $(0.90) Misses $(0.72) Estimate
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.72) by 25.52 percent. This is a 38.46 percent decrease over losses of $(0.65) per share
08-11 20:12
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
ArriVent BioPharma reported positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC, with plans to initiate the global pivotal Phase 3 ALPACCA study in 2H 2025. The first patient was dosed in the Phase 1 study of ARR-217, a CDH17-targeted ADC for gastrointestinal tumors. Top-line data from the FURVENT Phase 3 study for EGFR exon 20 insertion mutant NSCLC is expected in early 2026. The company had $254.5 million in cash and inve...
08-11 12:00
ArriVent Projects Topline Phase 3 FURVENT Data For Firmonertinib In First-Line NSCLC EGFR Exon20 Insertion Mutations In Early 2026
Enrollment in FURVENT was completed in Q1 2025Firmonertinib received FDA Breakthrough Therapy Designation in this patient population
07-21 20:13
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Goldman Sachs Reinstates Buy on ArriVent BioPharma, Announces $33 Price Target
Goldman Sachs analyst Corinne Johnson reinstates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and announces $33 price target.
07-11 02:13
